132 related articles for article (PubMed ID: 38478516)
1. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
[TBL] [Abstract][Full Text] [Related]
2. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
[TBL] [Abstract][Full Text] [Related]
3. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.
Min IM; Shevlin E; Vedvyas Y; Zaman M; Wyrwas B; Scognamiglio T; Moore MD; Wang W; Park S; Park S; Panjwani S; Gray KD; Tassler AB; Zarnegar R; Fahey TJ; Jin MM
Clin Cancer Res; 2017 Dec; 23(24):7569-7583. PubMed ID: 29025766
[No Abstract] [Full Text] [Related]
4. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
5. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
[No Abstract] [Full Text] [Related]
6. Early evolutionary divergence between papillary and anaplastic thyroid cancers.
Capdevila J; Mayor R; Mancuso FM; Iglesias C; Caratù G; Matos I; Zafón C; Hernando J; Petit A; Nuciforo P; Cameselle-Teijeiro JM; Álvarez C; Recio JA; Tabernero J; Matias-Guiu X; Vivancos A; Seoane J
Ann Oncol; 2018 Jun; 29(6):1454-1460. PubMed ID: 29648575
[TBL] [Abstract][Full Text] [Related]
7. Immune Landscape of Thyroid Cancers: New Insights.
Menicali E; Guzzetti M; Morelli S; Moretti S; Puxeddu E
Front Endocrinol (Lausanne); 2020; 11():637826. PubMed ID: 33986723
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
[TBL] [Abstract][Full Text] [Related]
9. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry.
Ahn J; Jin M; Song E; Ryu YM; Song DE; Kim SY; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Thyroid; 2021 Jan; 31(1):61-67. PubMed ID: 32611231
[No Abstract] [Full Text] [Related]
10. Tumor Mutation Burden Predicts Relapse in Papillary Thyroid Carcinoma With Changes in Genes and Immune Microenvironment.
Guo M; Chen Z; Li Y; Li S; Shen F; Gan X; Feng J; Cai W; Liu Q; Xu B
Front Endocrinol (Lausanne); 2021; 12():674616. PubMed ID: 34248843
[TBL] [Abstract][Full Text] [Related]
11. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
12. Papillary thyroid carcinoma behavior: clues in the tumor microenvironment.
Bergdorf K; Ferguson DC; Mehrad M; Ely K; Stricker T; Weiss VL
Endocr Relat Cancer; 2019 Jun; 26(6):601-614. PubMed ID: 30965283
[TBL] [Abstract][Full Text] [Related]
13. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
[TBL] [Abstract][Full Text] [Related]
15. Clear Cell Variant of Papillary Thyroid Carcinoma With Associated Anaplastic Thyroid Carcinoma: Description of an Extraordinary Case.
Juhlin CC; Höög A
Int J Surg Pathol; 2019 Sep; 27(6):658-663. PubMed ID: 30931661
[TBL] [Abstract][Full Text] [Related]
16. Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.
Giannini R; Moretti S; Ugolini C; Macerola E; Menicali E; Nucci N; Morelli S; Colella R; Mandarano M; Sidoni A; Panfili M; Basolo F; Puxeddu E
J Clin Endocrinol Metab; 2019 Aug; 104(8):3557-3575. PubMed ID: 30882858
[TBL] [Abstract][Full Text] [Related]
17. Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment.
Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Zhang J
Front Endocrinol (Lausanne); 2020; 11():570604. PubMed ID: 33193087
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
19. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ndishabandi D; Ashry T; McCarthy M; Zhou Z; Amin S; Freeman GJ; Alessandrini A; Parangi S
Br J Cancer; 2018 Nov; 119(10):1223-1232. PubMed ID: 30327563
[TBL] [Abstract][Full Text] [Related]
20. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
Gray KD; McCloskey JE; Vedvyas Y; Kalloo OR; Eshaky SE; Yang Y; Shevlin E; Zaman M; Ullmann TM; Liang H; Stefanova D; Christos PJ; Scognamiglio T; Tassler AB; Zarnegar R; Fahey TJ; Jin MM; Min IM
Clin Cancer Res; 2020 Nov; 26(22):6003-6016. PubMed ID: 32887724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
